<DOC>
	<DOCNO>NCT02056613</DOCNO>
	<brief_summary>Background : - Pluripotent stem cell cell convert type cell ( muscle , nerve , liver , etc. ) . Researchers collect blood sample develop way make special cell product call induced pluripotent stem cell ( iPSCs ) . iPSCs may use repair replace organ tissue , produce blood immune cell transfusion , correct inherit immune blood disease . iPSCs make many kind sample , skin , blood , hair . This different embryonic stem cell , derive embryos . Objectives : - To develop new method make iPSCs ; identify good way collect , produce , grow ; make iPSC bank . Eligibility : - Healthy adult adult already treatment protocol medical condition could treat iPSCs . Design : - All participant screen questionnaire , physical exam , blood HIV test . - All participant : - Will donate 4 tablespoon blood . It take needle vein arm . - Participants already another protocol : - Will blood collect , separate lab , iPSCs grow large number . Some may sample give back treatment . - Samples keep study 5 year participant withdraws study become ineligible participate , study close . If participant withdraw consent , may contact future donate .</brief_summary>
	<brief_title>Blood Collection From Healthy Volunteers Patients Production Clinical Grade Induced Pluripotent Stem Cell ( iPSC ) Products</brief_title>
	<detailed_description>Induced pluripotent stem cell ( iPSCs ) produce small quantity blood . Clinical protocol treat several disease use iPSCs cell derive iPSCs developed intramural investigator , i.e. , investigator National Institute Allergy Infectious Diseases ( NIAID ) National Eye Institute ( NEI ) . This clinical protocol allow personnel Cell Processing Service ( CPS ) Department Transfusion Medicine ( DTM ) collect blood healthy donor patient disease target IRB-approved treatment protocol manufacture iPSCs iPSC derive product support intramural investigator . CPS DTM submit Drug Master File ( DMF ) US Food Drug Administration ( FDA ) manufacture test product . When iPSCs use clinically case donor recipient iPSCs , ex vivo expand differentiate iPSCs ( autologous therapy ) . In case , healthy subject serve donor blood use start material manufacturing iPSCs ( allogeneic therapy ) match HLA antigen require healthy blood donor iPSC recipient . While method produce expand iPSCs describe , must modify periodically meet change Good Manufacturing Practices ( GMP ) requirement manufacture clinical cell gene therapy , therefore peripheral blood iPSCs normal donor need research development .</detailed_description>
	<criteria>INCLUSION CRITERIA RELATED OR THIRD PARTY DONORS ( ALLOGENEIC CELLS , INCLUDING RESEARCH DONORS ) AND AUTOLOGOUS DONORS Subjects meet ALL follow criterion consider enrollment study : 1 . Be great equal 18 year age , date enrollment . There upper age limit donor enrollment . 2 . Able provide inform consent . 3 . Meets donation requirement establish AABB FDA allogeneic autologous use exception hemoglobin/hematocrit . SUBJECT EXCLUSION CRITERIA ALLOGENEIC DONORS Subjects meet ANY follow criterion exclude participation study third party donor research volunteer : 1 . Medical history include follow , per AABB FDA requirement allogeneic use : Thrombocytopenia blood dyscrasia Bleeding diathesis Antibiotic use within prior 48 hour History cancer History exposure transfusion transmit disease include HIV hepatitis B C define Standards Blood Banking Transfusion Services , AABB . Travel area malaria endemic define CDC ( www.cdc.gov/travel ) . At risk possible transmission CreutzfeldtJakob Disease ( CJD ) Variant CreutzfeldtJakob Disease ( vCJD ) describe FDA Guidance Industry , January 9 , 2002 , Revised Preventive Measures Reduce Possible Risk Transfusion CreutzfeldtJakob Disease ( CJD ) Variant CreutzfeldtJakob Disease ( vCJD ) Blood Blood Products 2 . Febr le ( temperature &gt; 38 ( Infinite ) C ) 3 . Hemoglobin level African American woman &lt; 11.5 grams/dL Other woman &lt; 12.0 grams/dL Men &lt; 12.5 grams/dL 4 . HCT African American woman &lt; 34 % Other woman &lt; 36 % Men &lt; 38 % 5 . Platelets &lt; 150 time 103/microL 6 . Absolute neutrophil count &lt; 1.0 time 103/microL 7 . Positive test blood borne pathogen ( require Standards Blood Banks Transfusion Services , AABB . The currently require test include antiHIV1/2 , antiHCV , antiHBc , AntiHTLV I/II , antiT . Cruzi , HBsAg , syphilis , molecular test West Nile virus , HCV , HBV , HIV1 ) . SUBJECT EXCLUSION CRITERIA AUTOLOGOUS DONORS Subjects meet ANY follow criterion exclude participation study : 1 . Positive test antiHIV1/2 , antiHCV , HBsAg 2 . Does meet criterion establish NIH IRBapproved treatment protocol administration iPSCs , create protocol PI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 5, 2016</verification_date>
	<keyword>Blood Donation</keyword>
	<keyword>Tissue Procurement</keyword>
	<keyword>Cellular Therapies</keyword>
</DOC>